SML2177
S 38093-2
≥98% (HPLC)
别名:
4-(3-((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)propoxy)benzamide hydrochloride, S 38093, S-38093, S38093
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[H][C@@]([C@]1([H])C2)(CCC1)CN2CCCOC3=CC=C(C(N)=O)C=C3.Cl
InChI
1S/C17H24N2O2.ClH/c18-17(20)13-5-7-16(8-6-13)21-10-2-9-19-11-14-3-1-4-15(14)12-19;/h5-8,14-15H,1-4,9-12H2,(H2,18,20);1H/t14-,15+;
InChI key
AFSVOZDCVFYWFG-KBGJBQQCSA-N
Biochem/physiol Actions
Orally available selective histamine H3 receptor antagonist/inverse agonist with in vivo cognition-improving and antihyperalgesic efficacy.
S 38093 is an orally available compound with selective affinity toward histamine H3 receptor (human/mouse/rat H3R Ki = 0.2/1.44/8.8 μM), but not other histaminergic receptors, exhbiting both antagonist (KB = 652 nM against 300 nM (R)-α-Methylhistamine-induced GTPγS recruitment to mH3 CHO membrane; KB = 110 nM against 1 μM histamine-induced cAMP downregulation in hH3 CHO cells) and inverse agonist activity (hH3/rH3 HEK basal cAMP enhancing EC50 = 1.7/9 μM; 48% inhibition of ionomycin-induced hH3 or rH3 HEK AA reslease by 10 μM S 38093). S 38093 is reported to improve AD- and age-associated memory and cognition deficits in mice (0.1-3 mg/kg/day p.o.) and rats (0.1-10 mg/kg p.o. or i;p.), as well as display antiallodynic and antihyperalgesic efficacy in rat models of neuropathic pain in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Jean-Philippe Guilloux et al.
Scientific reports, 7, 42946-42946 (2017-02-22)
Strategies designed to increase adult hippocampal neurogenesis (AHN) may have therapeutic potential for reversing memory impairments. H3 receptor antagonists/inverse agonists also may be useful for treating cognitive deficits. However, it remains unclear whether these ligands have effects on AHN. The
Aurore Sors et al.
European journal of pharmacology, 803, 11-23 (2017-03-25)
Histaminergic H3 inverse agonists, by stimulating central histamine release, represent attractive drug candidates to treat cognitive disorders. The present studies aimed to describe the mechanistic profile of S 38093 a novel H3 receptors inverse agonist. S 38093 displays a moderate
Aurore Sors et al.
Frontiers in pharmacology, 7, 492-492 (2017-01-10)
Donepezil, an acetylcholinesterase inhibitor, induces only moderate symptomatic effects on memory in Alzheimer's disease patients. An alternative strategy for treatment of cognitive symptoms could be to act simultaneously on both histaminergic and cholinergic pathways, to create a synergistic effect. To
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2177-5MG | 04061835249213 |
| SML2177-25MG | 04061835249206 |